MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-15-2026
China Pharma Holdings Cash Conversion Cycle 2011-2026 | CPHI
Annual Cash Conversion Cycle China Pharma Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 139 | 164 | 150 | 110 | 106 | 121 | 110 | 174 | 248 | 225 | 243 | 614 | 758 | 747 | 504 | 216 | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 758 | 106 | 289 |
Quarterly Cash Conversion Cycle China Pharma Holdings
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 153 | 132 | 147 | - | 159 | - | - | - | 156 | 243 | 136 | - | 123 | 154 | 141 | - | 98.2 | 106 | 130 | - | 117 | 104 | 175 | - | 126 | 107 | 149 | - | 240 | 167 | 205 | - | 242 | 284 | 257 | - | 201 | 181 | 251 | - | 403 | 381 | 463 | - | 695 | 684 | 815 | - | 862 | 969 | 1.13 K | - | 852 | 716 | 651 | - | 487 | 539 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.13 K | 98.2 | 341 |
Cash Conversion Cycle of other stocks in the Drug manufacturers industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Endo International plc
ENDP
|
141 | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
55.1 | - | - | $ 36.6 M |  USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-227 | $ 5.6 | - | $ 83.2 M | USA |
 |
HEXO Corp.
HEXO
|
775 | - | 2.45 % | $ 38.1 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
-38 | - | 7.5 % | $ 6.35 M | USA |
 |
DURECT Corporation
DRRX
|
-4.1 K | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-224 | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
460 | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
-206 | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
-128 | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
61.7 | $ 2.63 | -1.87 % | $ 1.01 B | Canada |
 |
Athenex
ATNX
|
137 | - | -23.39 % | $ 1.76 M | USA |
 |
Harrow Health
HROW
|
-46.2 | $ 38.93 | 3.43 % | $ 1.43 B | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
192 | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
110 | - | - | $ 11.5 B | USA |
 |
Organogenesis Holdings
ORGO
|
106 | $ 2.41 | 2.99 % | $ 305 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
139 | - | -39.89 % | $ 27.7 M | USA |
 |
Pacira BioSciences
PCRX
|
209 | $ 22.74 | -1.09 % | $ 1.05 B | USA |
 |
Canopy Growth Corporation
CGC
|
174 | $ 0.98 | -1.71 % | $ 105 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
150 | $ 1.11 | 1.83 % | $ 1.38 M | USA |
 |
Aurora Cannabis
ACB
|
1.45 K | $ 2.95 | -2.96 % | $ 162 M | Canada |
 |
Jupiter Wellness
JUPW
|
-186 | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
173 | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
2.92 K | $ 1.03 | -2.83 % | $ 98.2 M | Canada |
 |
Tilray
TLRY
|
169 | $ 5.01 | 0.6 % | $ 3.1 B | Canada |
 |
Evolus
EOLS
|
74.8 | $ 6.75 | 0.3 % | $ 435 M | USA |
 |
Emergent BioSolutions
EBS
|
360 | $ 8.29 | -0.36 % | $ 444 M | USA |
 |
Veru
VERU
|
19.6 | $ 3.13 | 4.33 % | $ 45.8 M | USA |
 |
cbdMD
YCBD
|
83 | $ 0.67 | -2.33 % | $ 2.7 M | USA |
 |
Assertio Holdings
ASRT
|
467 | $ 23.5 | 0.09 % | $ 150 M | USA |
 |
ProPhase Labs
PRPH
|
136 | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-35 | - | - | $ 1.42 B | USA |
 |
Bausch Health Companies
BHC
|
79.8 | $ 4.99 | -1.38 % | $ 1.85 B | Canada |
 |
PetIQ
PETQ
|
53.8 | - | 1.64 % | $ 400 M | USA |
 |
Recro Pharma
REPH
|
105 | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
491 | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
2.74 | $ 4.09 | -3.31 % | $ 204 M | USA |
 |
PLx Pharma
PLXP
|
113 | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
150 | $ 16.32 | -0.97 % | $ 19 B | USA |
 |
Zomedica Corp.
ZOM
|
154 | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
14.6 K | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
57 | $ 0.64 | 2.74 % | $ 23 M | USA |
 |
TherapeuticsMD
TXMD
|
-723 | $ 2.28 | 3.64 % | $ 26.4 M | USA |